PMID- 20864814
OWN - NLM
STAT- MEDLINE
DCOM- 20110715
LR  - 20211020
IS  - 1554-8619 (Electronic)
IS  - 1554-8600 (Print)
IS  - 1554-8600 (Linking)
VI  - 6
IP  - 11
DP  - 2010 Nov
TI  - Concomitant or sequential administration of live attenuated Japanese encephalitis 
      chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind 
      phase II evaluation of safety and immunogenicity.
PG  - 906-14
LID - 10.4161/hv.6.11.12854 [doi]
AB  - A randomized, double-blind, study was conducted to evaluate the safety, 
      tolerability and immunogenicity of a live attenuated Japanese encephalitis 
      chimeric virus vaccine (JE-CV) co-administered with live attenuated yellow fever 
      vaccine (YF-17D strain; Stamaril(R), Sanofi Pasteur) or administered successively. 
      Participants (n = 108) were randomized to receive: YF followed by JE-CV 30 days 
      later, JE followed by YF 30 days later, or the co-administration of JE and YF 
      followed or preceded by placebo 30 days later or earlier. Placebo was used in a 
      double-dummy fashion to ensure masking. Neutralizing antibody titers against 
      JE-CV, YF-17D and selected wild-type JE strains was determined using a 50% 
      serum-dilution plaque reduction neutralization test. Seroconversion was defined 
      as the appearance of a neutralizing antibody titer above the assay cut-off 
      post-immunization when not present pre-injection at day 0, or a least a four-fold 
      rise in neutralizing antibody titer measured before the pre-injection day 0 and 
      later post vaccination samples. There were no serious adverse events. Most 
      adverse events (AEs) after JE vaccination were mild to moderate in intensity, and 
      similar to those reported following YF vaccination. Seroconversion to JE-CV was 
      100% and 91% in the JE/YF and YF/JE sequential vaccination groups, respectively, 
      compared with 96% in the co-administration group. All participants seroconverted 
      to YF vaccine and retained neutralizing titers above the assay cut-off at month 
      six. Neutralizing antibodies against JE vaccine were detected in 82-100% of 
      participants at month six. These results suggest that both vaccines may be 
      successfully co-administered simultaneously or 30 days apart.
FAU - Nasveld, Peter E
AU  - Nasveld PE
AD  - Australian Army Malaria Institute, Queensland, Australia.
FAU - Marjason, Joanne
AU  - Marjason J
FAU - Bennett, Sonya
AU  - Bennett S
FAU - Aaskov, John
AU  - Aaskov J
FAU - Elliott, Suzanne
AU  - Elliott S
FAU - McCarthy, Karen
AU  - McCarthy K
FAU - Kanesa-Thasan, Niranjan
AU  - Kanesa-Thasan N
FAU - Feroldi, Emmanuel
AU  - Feroldi E
FAU - Reid, Mark
AU  - Reid M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20101101
PL  - United States
TA  - Hum Vaccin
JT  - Human vaccines
JID - 101265291
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Japanese Encephalitis Vaccines)
RN  - 0 (Placebos)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Vaccines, Combined)
RN  - 0 (Yellow Fever Vaccine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral/blood
MH  - Double-Blind Method
MH  - Encephalitis, Japanese/*prevention & control
MH  - Female
MH  - Humans
MH  - Japanese Encephalitis Vaccines/*administration & dosage/adverse 
      effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neutralization Tests
MH  - Placebos/administration & dosage
MH  - Vaccination/*methods
MH  - Vaccines, Attenuated/administration & dosage/adverse effects/immunology
MH  - Vaccines, Combined/administration & dosage/adverse effects/immunology
MH  - Viral Plaque Assay
MH  - Yellow Fever/*prevention & control
MH  - Yellow Fever Vaccine/*administration & dosage/adverse effects/*immunology
MH  - Young Adult
PMC - PMC3060385
EDAT- 2010/09/25 06:00
MHDA- 2011/07/16 06:00
PMCR- 2010/11/30
CRDT- 2010/09/25 06:00
PHST- 2010/09/25 06:00 [entrez]
PHST- 2010/09/25 06:00 [pubmed]
PHST- 2011/07/16 06:00 [medline]
PHST- 2010/11/30 00:00 [pmc-release]
AID - 12854 [pii]
AID - 1554-8600-6-11-10 [pii]
AID - 10.4161/hv.6.11.12854 [doi]
PST - ppublish
SO  - Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.